- Home
- UNCY vs DTIL Comparison
UNCY vs DTIL Comparison
Compare UNCY & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- DTIL
- Stock Information
- Founded
- UNCY 2016
- DTIL 2006
- Country
- UNCY United States
- DTIL United States
- Employees
- UNCY N/A
- DTIL N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- DTIL Health Care
- Exchange
- UNCY Nasdaq
- DTIL Nasdaq
- Market Cap
- UNCY 56.4M
- DTIL 55.3M
- IPO Year
- UNCY 2021
- DTIL 2019
- Fundamental
- Price
- UNCY $4.70
- DTIL $4.71
- Analyst Decision
- UNCY Strong Buy
- DTIL Strong Buy
- Analyst Count
- UNCY 4
- DTIL 2
- Target Price
- UNCY $63.75
- DTIL $47.00
- AVG Volume (30 Days)
- UNCY 384.1K
- DTIL 167.1K
- Earning Date
- UNCY 08-14-2025
- DTIL 08-07-2025
- Dividend Yield
- UNCY N/A
- DTIL N/A
- EPS Growth
- UNCY N/A
- DTIL N/A
- EPS
- UNCY N/A
- DTIL N/A
- Revenue
- UNCY N/A
- DTIL $1,261,000.00
- Revenue This Year
- UNCY N/A
- DTIL N/A
- Revenue Next Year
- UNCY $1,178.98
- DTIL $53.21
- P/E Ratio
- UNCY N/A
- DTIL N/A
- Revenue Growth
- UNCY N/A
- DTIL N/A
- 52 Week Low
- UNCY $2.75
- DTIL $3.61
- 52 Week High
- UNCY $11.00
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- UNCY 52.02
- DTIL 50.82
- Support Level
- UNCY $3.97
- DTIL $4.27
- Resistance Level
- UNCY $4.43
- DTIL $5.13
- Average True Range (ATR)
- UNCY 0.25
- DTIL 0.32
- MACD
- UNCY 0.10
- DTIL -0.01
- Stochastic Oscillator
- UNCY 73.00
- DTIL 53.33
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.